vTv Therapeutics to Participate in Upcoming Investor Conferences

About this update from Vtv Therapeutics Inc.

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 11:20 AM ET Format: Presentation Only Location: Virtual Webcast Link TD Cowen 46th Annual Health Care Conference Date: Tuesday, March 3, 2026 Time: 9:50 AM ET Format: Presentation and 1x1 Meetings Location: Boston, MA Webcast Link About   vTv   Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by  cadisegliatin , currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at  vtvtherapeutics.com  or follow the company on  LinkedIn  or  X . About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin , acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated. Investor Contact John Fraunces LifeSci Advisors, LLC [email protected] Media Contact Caren Begun TellMed Strategies 201-396-8551 [email protected]

View stock analysis, news, and events for Vtv Therapeutics Inc.